Originally published by Robert Kraft.
Fierce Pharma Manufacturing reports that GlaxoSmithKline has recalled 128,704 Ventolin HFA inhalers “because some canisters may not contain sufficient propellant to deliver the 200 doses that its label said it can provide through the end of its shelf life.” The inhalers were manufactured at GSK’s plant in Zebulon, NC, which closed last summer after positive tests for Legionnaires’ disease.
From the news release of the American Association for Justice.
Curated by Texas Bar Today. Follow us on Twitter @texasbartoday.
from Texas Bar Today http://ift.tt/1W88XCu
via Abogado Aly Website
No comments:
Post a Comment